pan-RAS drugs for Pancreatic Ductal Adenocarcinoma
2 tracked pan-RAS drugs in the Pancreatic Ductal Adenocarcinoma race. The class explanation lives on the pan-RAS page; the full indication pipeline across every mechanism is on the Pancreatic Ductal Adenocarcinoma page.
1 approved / phase 41 Phase 2
Head-to-head evidence: Daraxonrasib vs ERAS-0015